Cytoreductive nephrectomy in metastatic renal cell carcinoma

Vitaly Margulis, Surena F. Matin, Christopher G. Wood

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Cytoreductive nephrectomy has an established role in management of metastatic renal cell carcinoma when performed in properly selected patients prior to administration of systemic cytokine therapy. Within the past several years, novel molecular targeted agents have not only revolutionized management of metastatic renal cell carcinoma but also created controversy regarding the necessity, patient selection for and timing of cytoreductive nephrectomy. RECENT FINDINGS: Benefits of targeted molecular therapeutics have largely been observed in the context of prior cytoreductive nephrectomy, and limited available evidence supports cytoreductive nephrectomy in appropriately selected patients with metastatic renal cell carcinoma who are candidates for targeted systemic therapy. Presurgical systemic therapy with targeted molecular agents is an attractive paradigm, which not only offers a rational approach to select patients who are most likely to benefit from cytoreductive nephrectomy but also allows access to treated tumor tissue to study molecular mechanisms of response and resistance. Surgical approaches increasingly utilized in patients with localized kidney cancer, such as nephron-sparing and minimally invasive techniques are similarly relevant and should be utilized, when appropriate, in patients with metastatic renal cell carcinoma. SUMMARY: Cytoreductive nephrectomy should be considered to provide a survival benefit for patients with metastatic renal cell carcinoma and should be used in patients who are candidates for systemic therapy before or after surgery.

Original languageEnglish (US)
Pages (from-to)474-480
Number of pages7
JournalCurrent Opinion in Urology
Volume18
Issue number5
DOIs
StatePublished - Sep 2008

Fingerprint

Nephrectomy
Renal Cell Carcinoma
Molecular Targeted Therapy
Kidney Neoplasms
Nephrons
Therapeutics
Patient Selection
Cytokines
Survival
Neoplasms

Keywords

  • Cytoreductive nephrectomy
  • Immunotherapy
  • Renal cell carcinoma
  • Targeted molecular therapy

ASJC Scopus subject areas

  • Urology

Cite this

Cytoreductive nephrectomy in metastatic renal cell carcinoma. / Margulis, Vitaly; Matin, Surena F.; Wood, Christopher G.

In: Current Opinion in Urology, Vol. 18, No. 5, 09.2008, p. 474-480.

Research output: Contribution to journalArticle

Margulis, Vitaly ; Matin, Surena F. ; Wood, Christopher G. / Cytoreductive nephrectomy in metastatic renal cell carcinoma. In: Current Opinion in Urology. 2008 ; Vol. 18, No. 5. pp. 474-480.
@article{75531f49b63c4cb592980e89c7dc1aa9,
title = "Cytoreductive nephrectomy in metastatic renal cell carcinoma",
abstract = "PURPOSE OF REVIEW: Cytoreductive nephrectomy has an established role in management of metastatic renal cell carcinoma when performed in properly selected patients prior to administration of systemic cytokine therapy. Within the past several years, novel molecular targeted agents have not only revolutionized management of metastatic renal cell carcinoma but also created controversy regarding the necessity, patient selection for and timing of cytoreductive nephrectomy. RECENT FINDINGS: Benefits of targeted molecular therapeutics have largely been observed in the context of prior cytoreductive nephrectomy, and limited available evidence supports cytoreductive nephrectomy in appropriately selected patients with metastatic renal cell carcinoma who are candidates for targeted systemic therapy. Presurgical systemic therapy with targeted molecular agents is an attractive paradigm, which not only offers a rational approach to select patients who are most likely to benefit from cytoreductive nephrectomy but also allows access to treated tumor tissue to study molecular mechanisms of response and resistance. Surgical approaches increasingly utilized in patients with localized kidney cancer, such as nephron-sparing and minimally invasive techniques are similarly relevant and should be utilized, when appropriate, in patients with metastatic renal cell carcinoma. SUMMARY: Cytoreductive nephrectomy should be considered to provide a survival benefit for patients with metastatic renal cell carcinoma and should be used in patients who are candidates for systemic therapy before or after surgery.",
keywords = "Cytoreductive nephrectomy, Immunotherapy, Renal cell carcinoma, Targeted molecular therapy",
author = "Vitaly Margulis and Matin, {Surena F.} and Wood, {Christopher G.}",
year = "2008",
month = "9",
doi = "10.1097/MOU.0b013e32830a4f21",
language = "English (US)",
volume = "18",
pages = "474--480",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Cytoreductive nephrectomy in metastatic renal cell carcinoma

AU - Margulis, Vitaly

AU - Matin, Surena F.

AU - Wood, Christopher G.

PY - 2008/9

Y1 - 2008/9

N2 - PURPOSE OF REVIEW: Cytoreductive nephrectomy has an established role in management of metastatic renal cell carcinoma when performed in properly selected patients prior to administration of systemic cytokine therapy. Within the past several years, novel molecular targeted agents have not only revolutionized management of metastatic renal cell carcinoma but also created controversy regarding the necessity, patient selection for and timing of cytoreductive nephrectomy. RECENT FINDINGS: Benefits of targeted molecular therapeutics have largely been observed in the context of prior cytoreductive nephrectomy, and limited available evidence supports cytoreductive nephrectomy in appropriately selected patients with metastatic renal cell carcinoma who are candidates for targeted systemic therapy. Presurgical systemic therapy with targeted molecular agents is an attractive paradigm, which not only offers a rational approach to select patients who are most likely to benefit from cytoreductive nephrectomy but also allows access to treated tumor tissue to study molecular mechanisms of response and resistance. Surgical approaches increasingly utilized in patients with localized kidney cancer, such as nephron-sparing and minimally invasive techniques are similarly relevant and should be utilized, when appropriate, in patients with metastatic renal cell carcinoma. SUMMARY: Cytoreductive nephrectomy should be considered to provide a survival benefit for patients with metastatic renal cell carcinoma and should be used in patients who are candidates for systemic therapy before or after surgery.

AB - PURPOSE OF REVIEW: Cytoreductive nephrectomy has an established role in management of metastatic renal cell carcinoma when performed in properly selected patients prior to administration of systemic cytokine therapy. Within the past several years, novel molecular targeted agents have not only revolutionized management of metastatic renal cell carcinoma but also created controversy regarding the necessity, patient selection for and timing of cytoreductive nephrectomy. RECENT FINDINGS: Benefits of targeted molecular therapeutics have largely been observed in the context of prior cytoreductive nephrectomy, and limited available evidence supports cytoreductive nephrectomy in appropriately selected patients with metastatic renal cell carcinoma who are candidates for targeted systemic therapy. Presurgical systemic therapy with targeted molecular agents is an attractive paradigm, which not only offers a rational approach to select patients who are most likely to benefit from cytoreductive nephrectomy but also allows access to treated tumor tissue to study molecular mechanisms of response and resistance. Surgical approaches increasingly utilized in patients with localized kidney cancer, such as nephron-sparing and minimally invasive techniques are similarly relevant and should be utilized, when appropriate, in patients with metastatic renal cell carcinoma. SUMMARY: Cytoreductive nephrectomy should be considered to provide a survival benefit for patients with metastatic renal cell carcinoma and should be used in patients who are candidates for systemic therapy before or after surgery.

KW - Cytoreductive nephrectomy

KW - Immunotherapy

KW - Renal cell carcinoma

KW - Targeted molecular therapy

UR - http://www.scopus.com/inward/record.url?scp=54549120308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54549120308&partnerID=8YFLogxK

U2 - 10.1097/MOU.0b013e32830a4f21

DO - 10.1097/MOU.0b013e32830a4f21

M3 - Article

C2 - 18670270

AN - SCOPUS:54549120308

VL - 18

SP - 474

EP - 480

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 5

ER -